行情

CLSN

CLSN

Celsion
NASDAQ

实时行情|Nasdaq Last Sale

0.9082
+0.0181
+2.03%
交易中 11:51 04/02 EDT
开盘
0.9000
昨收
0.8901
最高
0.9499
最低
0.8902
成交量
7.09万
成交额
--
52周最高
2.530
52周最低
0.6865
市值
2,657.13万
市盈率(TTM)
-1.1587
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CLSN价格均价为7.50,最高价位9.00,最低价为4.000。

EPS

CLSN 新闻

更多
  • Edited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMT
  • Thomson Reuters StreetEvents · 7小时前
  • Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 6天前
  • Celsion Corp. to Host Earnings Call
  • ACCESSWIRE · 03/26 14:00
  • Celsions OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm
  • GlobeNewswire · 03/26 13:00

所属板块

生物技术和医学研究
+2.38%
制药与医学研究
+1.53%

热门股票

代码
价格
涨跌幅

CLSN 简况

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
展开

微牛提供Celsion Corporation(NASDAQ-CLSN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CLSN股票新闻,以帮助您做出投资决策。